Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP-8374 (Primary) ; Pembrolizumab
  • Indications Bladder cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma Global Development

    • Most Recent Events

    • 28 Nov 2018 Planned number of patients changed from 400 to 363.
    • 28 Nov 2018 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.
    • 28 Nov 2018 Planned primary completion date changed from 1 Mar 2022 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top